Bearish Options Activity on Pfizer Inc. After Worse Fundamentals


 Bearish Options Activity on Pfizer Inc. After Worse Fundamentals

In today’s session Pfizer Inc. (PFE) recorded an unusually high (376) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the January, 2018 put, expecting serious PFE decrease. With 376 contracts traded and 79004 open interest for the Jan, 18 contract, it seems this is a quite bearish bet. The option with symbol: PFE180119P00035000 closed last at: $4.75 or 4.4% up. About 11.73 million shares traded hands. Pfizer Inc. (NYSE:PFE) has risen 8.50% since March 14, 2016 and is uptrending. It has outperformed by 2.89% the S&P500.

Analysts await Pfizer Inc. (NYSE:PFE) to report earnings on October, 25. They expect $0.62 earnings per share, up 3.33% or $0.02 from last year’s $0.6 per share. PFE’s profit will be $3.75B for 13.12 P/E if the $0.62 EPS becomes a reality. After $0.64 actual earnings per share reported by Pfizer Inc. for the previous quarter, Wall Street now forecasts -3.13% negative EPS growth.

Pfizer Inc. (NYSE:PFE) Ratings Coverage

Out of 18 analysts covering Pfizer (NYSE:PFE), 9 rate it a “Buy”, 0 “Sell”, while 9 “Hold”. This means 50% are positive. Pfizer has been the topic of 36 analyst reports since July 29, 2015 according to StockzIntelligence Inc. The stock of Pfizer Inc. (NYSE:PFE) earned “Buy” rating by Jefferies on Thursday, August 4. As per Tuesday, October 20, the company rating was upgraded by Cowen & Co. The firm has “Buy” rating given on Friday, August 14 by Piper Jaffray. The stock has “Overweight” rating given by Piper Jaffray on Friday, August 28. As per Thursday, July 14, the company rating was maintained by Jefferies. As per Monday, April 18, the company rating was maintained by Goldman Sachs. The firm has “Buy” rating by Jefferies given on Monday, June 20. The rating was maintained by Credit Suisse with “Outperform” on Monday, May 9. Suntrust Robinson upgraded the shares of PFE in a report on Wednesday, November 25 to “Neutral” rating. On Wednesday, April 6 the stock rating was initiated by Societe Generale with “Hold”.

According to Zacks Investment Research, “Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company’s diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer healthcare products. Pfizer’s Animal Health business unit discovers, develops and sells products for the prevention and treatment of diseases in livestock and companion animals. It sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, veterinarians, livestock producers, and grocery and convenience stores. Pfizer Inc. is headquartered in New York.”

Insitutional Activity: The institutional sentiment decreased to 1.03 in 2016 Q2. Its down 0.21, from 1.24 in 2016Q1. The ratio is negative, as 80 funds sold all Pfizer Inc. shares owned while 704 reduced positions. 127 funds bought stakes while 678 increased positions. They now own 4.15 billion shares or 5.76% less from 4.40 billion shares in 2016Q1.
Eagle Ridge Investment Mgmt owns 11,616 shares or 0.09% of their US portfolio. Forbes J M Llp, a Massachusetts-based fund reported 322,387 shares. Palouse Capital Mngmt, a Washington-based fund reported 244,304 shares. Rafferty Asset Mngmt Ltd Co holds 119,125 shares or 0.28% of its portfolio. Brighton Jones Limited Liability has 0.25% invested in the company for 40,027 shares. Virginia Retirement Et Al owns 1.31 million shares or 0.68% of their US portfolio. Clearbridge Ltd Com owns 11.73 million shares or 0.49% of their US portfolio. Veritable Limited Partnership accumulated 0.32% or 354,236 shares. Franklin Street Advsrs Incorporated Nc holds 0.24% or 36,423 shares in its portfolio. Pacific Glob Invest Mgmt reported 62,021 shares or 0.51% of all its holdings. Gofen Glossberg Ltd Liability Il holds 0.74% or 505,144 shares in its portfolio. Advent Cap Mgmt De accumulated 0.01% or 14,000 shares. Coastline holds 0.8% or 112,970 shares in its portfolio. Horan Cap Advsrs Ltd Com last reported 8,437 shares in the company. Chatham Gp reported 41,648 shares or 0.45% of all its holdings.

Insider Transactions: Since May 3, 2016, the stock had 0 buys, and 13 selling transactions for $36.04 million net activity. $1.00M worth of Pfizer Inc. (NYSE:PFE) was sold by LANKLER DOUGLAS M. 76,116 Pfizer Inc. (NYSE:PFE) shares with value of $2.57M were sold by SUSMAN SALLY. 192,000 shares were sold by DAMELIO FRANK A, worth $6.46 million on Tuesday, May 10. Dolsten Mikael sold $2.26 million worth of Pfizer Inc. (NYSE:PFE) on Wednesday, May 4. $1.40 million worth of Pfizer Inc. (NYSE:PFE) was sold by YOUNG JOHN D on Tuesday, May 10. On Wednesday, May 11 OLSON LAURIE J sold $157,450 worth of the stock or 4,700 shares. CANGIALOSI LORETTA V sold $2.92 million worth of Pfizer Inc. (NYSE:PFE) on Tuesday, May 24.

Pfizer Inc. is a research-based global biopharmaceutical company. The company has a market cap of $196.80 billion. The Firm is engaged in discovering, developing and manufacturing of healthcare products. It has a 28.88 P/E ratio. The Company’s divisions include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

PFE Company Profile

Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research global biopharmaceutical company. The Firm is engaged in discovering, developing and manufacturing of healthcare products. The Company’s divisions include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The Company’s portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. The Company’s biopharmaceutical products include Lipitor, Sutent and the Premarin family of products. The Company’s biotechnology products include BeneFIX, ReFacto and Xyntha.

More notable recent Pfizer Inc. (NYSE:PFE) news were published by: which released: “Pfizer Becomes Oversold” on October 17, 2016, also with their article: “3 Reasons Pfizer Is A Screaming Buy Right Now” published on October 17, 2016, published: “Pfizer Divests Hospira Infusion Systems To ICU, Retaining An Interest In The …” on October 10, 2016. More interesting news about Pfizer Inc. (NYSE:PFE) were released by: and their article: “Pfizer Loses U.K. Patent Appeal Over $4.8 Billion Lyrica Drug” published on October 13, 2016 as well as‘s news article titled: “Pfizer: What Will The Dividend Increase Be?” with publication date: October 14, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply